TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32746647

Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) and antidiarrhoeal treatments (TAD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Antidiarrhoeal treatments only (TADS)
Number of subjects: 15
Study: 36062951

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2931

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2931
Study: 33464934

Group type: EXPERIMENTAL
Intervention: Structured communication rehabilitation programme (EG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Communication group based on free conversation (CG)
Number of subjects: 12
Study: 33166718

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg fixed dose)
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 1512

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1512

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1512
Study: 32472012

Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg nomegestrol acetate and 1.5 mg estradiol)
Number of subjects: 69

Group type: COMPARATOR
Intervention: GS/EE (0.075 mg gestodene and 0.02 mg ethinyl estradiol)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 69

Group type: COMPARATOR
Intervention: GS/EE
Number of subjects: 69
Study: 34543276

Group type: EXPERIMENTAL
Intervention: High urinary volume (HV)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Low urinary volume (LV)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Voiding status (VC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Not able to void (NVC)
Number of subjects: 155
Study: 32279690

Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) supplementation for 50 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Polydextrose (PD) supplementation for 50 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35772671

Group type: EXPERIMENTAL
Intervention: Active DBS
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham DBS
Number of subjects: 25
Study: 33789683

Group type: EXPERIMENTAL
Intervention: HIIT-style VPA intervention (additional 10 min of VPA per PE lesson for one academic year)
Number of subjects: 18261

Group type: COMPARATOR
Intervention: PE as usual (control condition)
Number of subjects: 18261
Study: 32766808

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine (OMM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Concussion Education
Number of subjects: 30
Study: 35134970

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg IV every 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 34433598

Group type: EXPERIMENTAL
Intervention: VR (eHBB+digital guide)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Video (video+digital guide)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control (digital guide only)
Number of subjects: 274
Study: 33472510

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavior Therapy (gCBT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48
Study: 34022937

Group type: EXPERIMENTAL
Intervention: Single-dose tranexamic acid
Number of subjects: 20127

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 20127
Study: 36279220

Group type: EXPERIMENTAL
Intervention: Standard CBT (nine sessions prior to exposure initiation)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Adapted CBT (exposure following the fifth session)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Cognitive skills introduction
Number of subjects: 148
Study: 34333473

Group type: EXPERIMENTAL
Intervention: 3D VR models
Number of subjects: 10

Group type: COMPARATOR
Intervention: 2D images
Number of subjects: 10
Study: 32502550

Group type: EXPERIMENTAL
Intervention: Linked-color imaging (LCI)
Number of subjects: 649

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 649
Study: 34579066

Group type: EXPERIMENTAL
Intervention: Test product (prolonged-release AA mixture formulated with Physiomimic Technology™)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference product (free AA mixture)
Number of subjects: 30
Study: 32097999

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (12 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 45
Study: 36201813

Group type: EXPERIMENTAL
Intervention: Internet-delivered treatment for anxiety and depression over 8 weeks
Number of subjects: 576
Study: 33762655

Group type: EXPERIMENTAL
Intervention: Volume‐oriented incentive spirometry (VIS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Flow‐oriented incentive spirometry (FIS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diaphragmatic breathing exercise (DBE)
Number of subjects: 72
Study: 32778491

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Bypass surgery (BS)
Number of subjects: 377
Study: 33676429

Group type: EXPERIMENTAL
Intervention: Blended AUD treatment (face-to-face contact with a therapist combined with internet modules)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Face-to-face treatment only (treatment as usual, TAU)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Blended AUD treatment
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Face-to-face treatment only (TAU)
Number of subjects: 1800
Study: 35287694

Group type: EXPERIMENTAL
Intervention: 6 hours of passive subdural drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 hours of passive subdural drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24 hours of passive subdural drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drain-related complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complications related to immobilization and mortality
Number of subjects: 0
Study: 34349372

Group type: COMPARATOR
Intervention: Combined spinal-epidural (CSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural (EPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dural puncture epidural (DPE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidural (EPL) and Dural puncture epidural (DPE)
Number of subjects: 0
Study: 34801738

Group type: EXPERIMENTAL
Intervention: Umifenovir (800 mg BID, maximum 14 days)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 32170359

Group type: EXPERIMENTAL
Intervention: Well-developed collateralization (Rentrop grade 2 or 3)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Poor collateralization (Rentrop grade 0 or 1)
Number of subjects: 95
Study: 36426809

Group type: EXPERIMENTAL
Intervention: Morphine (group M)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oxycodone (group O)
Number of subjects: 140
Study: 34442453

Group type: EXPERIMENTAL
Intervention: Kinesio tape
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo kinesio tape
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo auricular acupressure
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 36200632

Group type: EXPERIMENTAL
Intervention: Direct-to-consumer advertising for heart disease medications (treatment 1)
Number of subjects: 2874

Group type: EXPERIMENTAL
Intervention: Direct-to-consumer advertising for heart disease medications with price disclosure (treatment 2)
Number of subjects: 2874

Group type: COMPARATOR
Intervention: Nonpharmaceutical advertising (control group)
Number of subjects: 2874
Study: 34983456

Group type: EXPERIMENTAL
Intervention: Adapted INTERGROWTH-21st Project Neurodevelopment Assessment (INTER-NDA)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Non-specialist child development assessors
Number of subjects: 37
Study: 35368362

Group type: EXPERIMENTAL
Intervention: AVF ligation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 35380934

Group type: EXPERIMENTAL
Intervention: Care seeking for mental or sexual and reproductive health
Number of subjects: 2084

Group type: EXPERIMENTAL
Intervention: General care seeking reasons
Number of subjects: 2084

Group type: COMPARATOR
Intervention: Care seeking specifically for SV
Number of subjects: 2084
Study: 34121063

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 73
Study: 32933927

Group type: EXPERIMENTAL
Intervention: 8-week pulmonary rehabilitation programme
Number of subjects: 72

Group type: COMPARATOR
Intervention: 12-week pulmonary rehabilitation programme
Number of subjects: 72
Study: 34147912

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (100 mcg twice daily) with olfactory training for 4 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sodium chloride (0.9%) with olfactory training for 4 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray with olfactory training
Number of subjects: 80
Study: 32066345

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided radiotherapy (MRgRT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Linear accelerator (standard treatment)
Number of subjects: 9
Study: 34453327

Group type: EXPERIMENTAL
Intervention: ATV-PG/AQ
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ATV-PG
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: AQ
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 33279295

Group type: EXPERIMENTAL
Intervention: Quiet group (treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-quiet group (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 0
Study: 35294126

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE50)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control group (Naoxinqing tablet - NXQ)
Number of subjects: 404
Study: 32941704

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting overall survival (OS) rates
Number of subjects: 66192

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting 3- and 5-year OS rates
Number of subjects: 66192

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram for predicting OS
Number of subjects: 66192

Group type: EXPERIMENTAL
Intervention: Prognostic nomogram
Number of subjects: 66192
Study: 35669313

Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate Intramuscular Injection (DMPA-IM)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Levonorgestrel Implant (LNG)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Copper Intrauterine Device (IUD)
Number of subjects: 401
Study: 32701954

Group type: EXPERIMENTAL
Intervention: GoActive intervention (12-week school-based programme)
Number of subjects: 2862

Group type: COMPARATOR
Intervention: Control group (standard school practice)
Number of subjects: 2862

Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 2862
Study: 35634761

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over M1 cortex (2 mA, 20 min for 3 days)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over left DLPFC (2 mA, 20 min for 3 days)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 67
Study: 33723346

Group type: EXPERIMENTAL
Intervention: 1E10 CFU of E. coli strain E1392/75-2A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5E10 CFU of E. coli strain E1392/75-2A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1E10 CFU of E. coli (second challenge)
Number of subjects: 0
Study: 32719903

Group type: EXPERIMENTAL
Intervention: FTY-ND (fingolimod-nondaily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: FTY-ED (fingolimod-everyday)
Number of subjects: 72
Study: 35043663

Group type: EXPERIMENTAL
Intervention: Early rhythm control (n=194)
Number of subjects: 300
Study: 33852718

Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 50
Study: 33804409

Group type: EXPERIMENTAL
Intervention: High social status condition
Number of subjects: 132

Group type: COMPARATOR
Intervention: Low social status condition
Number of subjects: 132
Study: 36399962

Group type: EXPERIMENTAL
Intervention: Depictions of male, older, and heroin deaths
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Older decedent (ecstasy)
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Older ecstasy decedent
Number of subjects: 1280
Study: 32930994

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Open-label treatment (previous placebo)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Open-label treatment (previous 120 mg)
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Open-label treatment (previous 240 mg)
Number of subjects: 1113
Study: 33115727

Group type: EXPERIMENTAL
Intervention: Endoscopic suture gastroplasty (E‐ESG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lifestyle modification alone (control group)
Number of subjects: 71
Study: 35175308

Group type: COMPARATOR
Intervention: Intravenous Methylprednisolone (IVMP)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 419
Study: 32888343

Group type: EXPERIMENTAL
Intervention: Electronic tablets
Number of subjects: 41866

Group type: COMPARATOR
Intervention: Paper-and-pencil
Number of subjects: 41866
Study: 32552839

Group type: EXPERIMENTAL
Intervention: Goal-directed checklist for brain-dead potential organ donor management
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard ICU care
Number of subjects: 63
Study: 35554079

Group type: EXPERIMENTAL
Intervention: TrimRox, a stimulant‐ and sugar‐free Prodosomed® TRCAP21 nutraceutical technology, utilizing six standardized extracts.
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract).
Number of subjects: 9
Study: 34513067

Group type: EXPERIMENTAL
Intervention: Inherited metabolic disease (IMD) diagnosed patients (Group 1, n=8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transient hyperammonemia patients (Group 2, n=12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diagnostic model for predicting IMD risk
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anemia in infants with IMD
Number of subjects: 20
Study: 34872339

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 310
Study: 33370864

Group type: EXPERIMENTAL
Intervention: Older adults from urban areas
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Married individuals
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Individuals with tertiary education
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Unemployed individuals
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Diagnosed with hypertension
Number of subjects: 3977

Group type: EXPERIMENTAL
Intervention: Diagnosed with diabetes mellitus
Number of subjects: 3977
Study: 33759620

Group type: EXPERIMENTAL
Intervention: 4-h TRF (eating only between 3 and 7 p.m.)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 6-h TRF (eating only between 1 and 7 p.m.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no meal timing restrictions)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 4-h TRF
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 6-h TRF
Number of subjects: 49
Study: 33480964

Group type: EXPERIMENTAL
Intervention: Restarting antiplatelet treatment in patients with intracerebral haemorrhage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Number of subjects: 0
Study: 34585215

Group type: EXPERIMENTAL
Intervention: Single dose 10 mg/kg intravenous
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Single dose 20 mg/kg intravenous
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Single dose 40 mg/kg intravenous
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multiple doses 10 mg/kg every 2 weeks for 24 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multiple doses 10 mg/kg every 4 weeks for 72 weeks
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Multiple doses 20 mg/kg every 4 weeks for 72 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 33067698

Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard of Care (SoC) regimens (bortezomib- or thalidomide-based)
Number of subjects: 350
Study: 34347564

Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO intervention
Number of subjects: 311

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 311
Study: 32416073

Group type: EXPERIMENTAL
Intervention: Camrelizumab (200 mg every 2 weeks)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Chemotherapy (docetaxel 75 mg/m2 every 3 weeks or irinotecan 180 mg/m2 every 2 weeks)
Number of subjects: 457
Study: 35682322

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 388
Study: 34135015

Group type: EXPERIMENTAL
Intervention: Liraglutide plus metformin (L+M)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric band surgery (LB)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Glargine followed by metformin (G/M)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 358
Study: 34379025

Group type: EXPERIMENTAL
Intervention: Oral herbal supplement 1650 mg/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Oral herbal supplement 3300 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo 3300 mg/day
Number of subjects: 55
Study: 34952747

Group type: EXPERIMENTAL
Intervention: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence; 12 weeks duration, incentives for negative urine tests (EtG < 150 ng/mL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-contingent (NC) Control group; 12 weeks duration, incentives for submitting urine samples regardless of abstinence
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Culturally tailored contingency management (CM) intervention targeting alcohol abstinence
Number of subjects: 158
Study: 33043352

Group type: EXPERIMENTAL
Intervention: Autologous concentrated growth factor fibrin solution + Bio‐Oss bone powder
Number of subjects: 83

Group type: COMPARATOR
Intervention: Bio‐Oss bone powder alone
Number of subjects: 83
Study: 34979216

Group type: COMPARATOR
Intervention: Protons
Number of subjects: 186

Group type: COMPARATOR
Intervention: Photons
Number of subjects: 186
Study: 32174349

Group type: EXPERIMENTAL
Intervention: Syringe adapter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ring‐finger method
Number of subjects: 20

Group type: COMPARATOR
Intervention: Middle‐finger method
Number of subjects: 20
Study: 34390049

Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 35098554

Group type: EXPERIMENTAL
Intervention: NP001
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 36468339

Group type: EXPERIMENTAL
Intervention: 4-week online psychosocial intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 0
Study: 34217230

Group type: EXPERIMENTAL
Intervention: Tailored intervention to reduce inappropriate psychotropic drug use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 0
Study: 32762997

Group type: EXPERIMENTAL
Intervention: Time to Think (TTT)
Number of subjects: 613

Group type: COMPARATOR
Intervention: No Time to Think (NTTT)
Number of subjects: 613
Study: 35863993

Group type: EXPERIMENTAL
Intervention: Multimedia-based education (MBE) including watching two videos followed by focused physician counseling
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard physician education (SPE)
Number of subjects: 75
Study: 33388204

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich diet (PR-diet)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control diet (C-diet)
Number of subjects: 66
Study: 34445969

Group type: EXPERIMENTAL
Intervention: Patient decision aid (DA) on treatment of depression
Number of subjects: 504

Group type: COMPARATOR
Intervention: No decision aid (Control)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Matched treatment preference
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Avoiding taking anti-depressants
Number of subjects: 504
Study: 35396313

Group type: EXPERIMENTAL
Intervention: Virtual exercise prehabilitation intervention
Number of subjects: 0
Study: 34872085

Group type: EXPERIMENTAL
Intervention: Blood kidney injury molecule 1 (KIM-1)
Number of subjects: 5131

Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF)
Number of subjects: 5131
Study: 35983809

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg every 3 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32735704

Group type: EXPERIMENTAL
Intervention: HL151 (20 mg orally once daily for 4 weeks)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 33211519

Group type: EXPERIMENTAL
Intervention: RTM (Reconsolidation of Traumatic Memories)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 30
Study: 35700205

Group type: EXPERIMENTAL
Intervention: Olotillo × Tuxpeño race in Myroxylon with 2.8 m × 2.0 arrays and monoculture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Three native maize races
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agroforestry systems (ASs)
Number of subjects: 0